Eli Lilly seems to be a great stock that can be bought due to recent unexpected weakness.
Summit is an upcoming drug manufacturer to get ready to hit your step.
The latest sale of Vertex Pharmaceuticals offers a huge purchase.
10 shares we like more than Eli Lilly ›
We are good at the home stretch in 2025. August is more than halfway. However, in a year – and this month – investing in stocks that have a lot of time to get a huge return.
Three co -authors of Motley Fool believe they found fantastic growth actions in August. That’s why they chose Eli Lilly(NYS: LLY)Is it Summit therapy(Nasdaq: SMMT)and Vertex Pharmaceuticals(Nasdaq: VRTX);
Image Source: Getty Images.
David Jagielski(Eli Lilly): Eli Lilly’s shares got into Tailin earlier this month after the company announced its latest earnings. Despite the news that the company is causing fantastic growth due to its GLP-1 drug success and much more growth on the horizon, this year there was a burst of a bear. Eli Lilly’s shares decreased by about 19%since the beginning of the year (from August 8).
The health care company increased its sales by 41% in the first six months of the first six years, with a total of over $ 28 billion (which is about the company reported all 2022).
However, it turned out that investors have been caused by investors to sell the reason. The tablets helped people lose almost 12% of their weight during the late stage, but the 15% missed the analysts hoped to see. Eli Lilly’s expectations will be a clear market leader at weight loss, investors do not want to accept anything that not only dominates.
However, buying Eli Lilly for weakness offers an intriguing option, especially if you are a long -term investor. Given strong operations, Mounjar and Zepbound, a very successful GLP-1 medicine, and upload more development products, I strongly believe it will be the first health care that has reached the top of the $ 1 trillion market in the future. After joining this week, its market value was about $ 560 billion; These are stocks that can have a huge runway.
While the latter news about Orfordron may be disappointed, Eli Lilly’s business still seems incredible, and buying Pharma shares can currently provide a great opportunity.
Keith speeighs (Summit Therapeutics): Unlike Eli Lilly, Summit Therapeutics does not receive billions of dollars. It does not even have a proven product on the market. However, I think you can glue a bold “yet” at the end of both previous statements. Summit is the upcoming drug manufacturer who I think is about to hit his step.
What is my optimistic perspective? Less than three months ago, Summit announced the best results of the world -first phase 3 clinical trial, which assesses Ivonenescimaba, in combination with chemotherapy as a second -order treatment with non -molar lung cancer (NSCLC). Combined therapy reduced the risk of progression or death by 48%compared to chemotherapy alone.
Based on the results of this clinical trial, Summit plans to submit the Biologicals License Application (bla) to the US Food and Drug Administration (FDA) to confirm Ivonenescimab and chemotherapy as a second -line NSCLC treatment. There is no guarantee of the FDA approval. However, the fact that there are no current FDA -approved treatments that have shown statistically significant overall benefits of survival in this indication give investors more reasons to expect success.
If Summit wins this FDA approval, but it may be just the tip of the iceberg. The company also performs phase 3 tests to evaluate Ivonessimab chemotherapy as first-line NSCLC treatment and as monotherapy in the treatment of metastatic NSCLC patients with high PD-L1 expression. If these studies are fine (and I suspect they will do it), I predict that a summit can earn a place among the largest reserves of 21st century cancer treatment.
Prosper Junior Bakiny (Vertex Pharmaceuticals): It was a difficult year for Vertex Pharmaceuticals, a leading biotechnology company. The drug manufacturer has faced several questions, and the last time its shares fell after clinical failures associated with the VX-993 pain test therapy. The VX-993 did not match the 2-phase 2 clinical study of its primary outcome.
Vertex shares decreased by 2%this year while S&P 500 increases by 8%. Investors, focusing on long games, can now be a great time to buy. Vertex Pharmaceuticals provides consistent income and income, and also has an expanding product series, a deep pipeline and a proven culture of innovation.
In the second quarter, the company’s revenue increased by 12% per year – a strong score of the biotechnology giant – to $ 2.96 billion.
The company’s long -term cystic fibrosis franchise is still working well. This should be continued long enough to make Vertex newer products, including Casgevy, which treats a pair of rare blood diseases, and Journavx acute pain to start a significant contribution to its top line. In the end, both could reach BlockBuster status.
And by then, Vertex should be able to release even newer medicines. The company’s type 1 diabetes therapy Zimacel does well in clinical trials and may receive approval for the next two years.
Vertex Pharmaceuticals should continue to innovate for a long time, taking into account multiple products through the late and mid -stage pipeline. All of these factors make Vertex prospects attractive. Currently, the company’s shares may be lower, but at the current level, they could provide higher return over the next five years. That is why the stock is so attractive.
Before buying Eli Lilly, consider this:
Motley Fool Stock Advisor A team of analysts just found what they think is 10 best stocks Investors to buy now … and Eli Lilly was not one of them. 10 stocks that reduced the incision can return the monster in the coming years.
Consider when Netflix This list consisted of 2004. December 17th … If you have invested $ 1,000 during our recommendation, at our recommendation, You would have $ 668 155!* Or when Nvidia Made this list in 2005. April 15 … If you have invested $ 1,000 during our recommendation, at our recommendation, You would have $ 1,106,071!*
Now it is worth mentioning Share advisor The average return is 1 070%-S&P 500, compared to 184 percent. Share advisor;
See. 10 stocks »
*The stock advisor returns from 2025. August 13
David Jagielski has no position in any of the above shares. Keith Spyights occupies Vertex Pharmaceuticals. Prosper Junior Bakiny holds Eli Lilly and Vertex Pharmaceuticals. Motley fool is a position and recommends Summit Therapeutics and Vertex Pharmaceuticals. The Motley fool has a disclosure policy.
